Uncategorized

Cancer, immune drugmakers dominate VC funding so far in 2026

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.

​Read More

Published

on

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.

​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version